Wall Street Signals: Latest News : $AVCO Avalon GloboCare Corp. Expands IP Portfolio; Files 16 New Patent Applications

Latest News : $AVCO Avalon GloboCare Corp. Expands IP Portfolio; Files 16 New Patent Applications


Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that the Company has jointly filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology. Patents were filed with the U.S. Patent and Trademark Office (USPTO), the China National Intellectual Property Administration (CNIPA), and under the Patent Cooperation Treaty (PCT) covering 36 countries.

The new intellectual property covers three core patent families:

  • Engineering and bio-manufacturing of novel chimeric antigen receptor (CAR) T-cells related to the mRNA-based Flash-CARTM cellular therapy platform. This technology has been applied to Avalon’s AVA-011 CAR-T cell therapy candidate, which is currently at the process development stage to generate cGMP-grade CAR-T cells for upcoming first-in-human clinical trials.
  • Soluble, antibody-like cytokine/chemokine decoy receptors derived using the QTY protein design, with potential applications including mitigation of the “cytokine storm” associated with COVID-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies.
  • Novel S-layer coated emulsion technology (SLET)-derived fusion proteins intended for mucosal vaccine development, which are designed to trigger robust protective immune responses at the predominant sites of pathogen infection. The SLET platform provides a “molecular GPS system” to guide the trafficking and delivery of a payload to a targeted destination in the body.

"These most recent patent applications harden and extend our strong IP portfolio, both in the U.S. what's more, universally," said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. "We are particularly regarded to join forces with a few driving worldwide scholarly specialists and organizations in the field of cell treatment, as co-creators of the advances. We accept these patent applications will expand our geographic IP insurance and are coordinated to augment the term of the licenses into the indefinite future. These licenses are inside our center skills in the space of CAR-T, QTY protein plan, and S-layer advancements, in this way upgrading our situation as a forerunner in immuno-oncology and cell prescriptions. On the whole, we accept every one of these licenses covers treatments and advances that target enormous, addressable business sectors. They are completely upheld by solid preclinical information as we quickly advance towards first-in-human clinical preliminaries."

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with a unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), and exosome technology (ACTEX™), regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.

For the latest updates on Avalon GloboCare's developments, please follow our Twitter at @avalongc_avco

Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728